

Table S1 IEC and IRB Information

Country/region	Site number	IRB number/local decision number	IEC/IRB
Hong Kong	1001	IRB00002883	Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee, 8/F, Lui Chi Woo Clinical Science Building, Prince of Wales Hospital, Shatin, Hong Kong, China
	1002	IRB00005123	Institutional Review Board of the University of Hong Kong, Hospital Authority Hong Kong West Cluster, Rm 901, Administration Block, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China
Indonesia	2001	IRB00003589	Health Research Ethic Committee Faculty of Medicine University of Indonesia/Cipto Mangunkusumo Hospital Jl. Salemba Raya No. 6, Jakarta Pusat, 10430 Jakarta, Indonesia
Malaysia	3001	IRB00004527	Medical Research Ethics Committee, University Malaya Medical Center, Lembah Pantai, 59100 Kuala Lumpur, Malaysia
	3002	IRB00001971	Central Ethics Committee, Medical Research Ethics Committee (MREC) Ministry of Health Malaysia, c/o Institute for Health Management, Block A, Kompleks Institut Kesihatan Negara (NIH) No. 1 Jalan Setia Murni U13/52, Seksyen U13, Bandar Setia Alam, 40170 Shah Alam, Selangor, Malaysia
Philippines	4001	IRB00008554	Makati Medical Center Institutional Review Board, 7th Floor, Keyland Center, 143 Dela Rosa cor. Adelantado Sts. Legaspi Village, Makati City, Philippines
	4002	2016-053	Cardinal Santos Medical Center (CSMC) Research Ethics Review Committee (RERC), Office of Research Ethics Review Committee 3rd Floor, Medical Arts Building (MAB) 1 Cardinal Santos Medical Center, #10 Wilson St., Greenhills, San Juan City 1502, Philippines
	4003	IRB00012685	Manila Doctors Hospital Institutional Review Board, 8th floor, Norberto Ty Medical Tower 2, Manila Doctors Hospital, 664 T.M. Kalaw St., Ermita, Manila 1000, Philippines
Singapore	5001, 5002, and 5003	IRB00004105, IRB00004106, IRB00004107, IRB00004108, IRB00006587, IRB00008208, IRB00012779	Central Institutional Review Board, Domain Specific Review Board, Domain Specific Review Board (DSRB), c/o National Healthcare Group, NHG Group Research, Nexus @One-North (South Tower), No. 3 Fusionopolis Link, #03-08, Singapore 138543, Singapore
Taiwan	6001	IRB00004911	Institutional Review Board of Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung 40705
	6002	CMUH105-REC2-108	Research Ethics Committee of China Medical University Hospital, 2 Yude Road, Taichung 40447
	6003	IRB00008540	Institutional Review Board, Tri-Service General Hospital No. 325, Sec 2, Cheng-Kung Rd, Neihu, Taipei 11490
Thailand	7001	IRB00006011, IRB00006012, IRB00006013, IRB00009913	Research Ethics Committee Faculty of Medicine Chiang Mai University, 3rd floor of Registration Building 110, Intavaroros Road, Muang, Chiang Mai 50200, Thailand
	7002	IRB00001607	Institutional Review Board, Faculty of Medicine, Chulalongkorn University, Research Administration Section, Research Affairs, Faculty of Medicine, Chulalongkorn University, 3rd floor of Ananda Mahidol Building, Henri Dunant Road, Pathumwan, Bangkok 10330, Thailand
	7003	IRB00005261	Siriraj Institutional Review Board, Faculty of Medicine Siriraj Hospital, Mahidol University, Room 210, 2nd floor of His Majesty the King's 80th Birthday Anniversary 5th December 2007 Building, 2, Wang Lang Road, Siriraj Bangkoknoi, Bangkok 10700, Thailand
	7004	IRB00003039, IRB00010134	Office of Human Research Ethics Committee Faculty of Medicine, Prince of Songkla University, 15, Karnjanavanit Road, Hat Yai, Songkla, Thailand
	Regulatory agency	TFDA-17-025	Thai FDA: Food and Drug Administration 88/24 Tiwanon Road, Nonthaburi 11000, Thailand
Vietnam	8001	Decision 122/HDDD	The Ethics Committee in Biomedical Research of Cho Ray Hospital, 201B Nguyen Chi Thanh, District 5, Ho Chi Minh City, Vietnam
	8002	Decision 3870/QD-DHYD	The Ethics Committee in Biomedical Research of University Medical Center Ho Chi Minh City, 215 Hong Bang, Ward 11, District 5, Ho Chi Minh City, Vietnam
	Ministry of Health	Decision 1122/QD-BYT	National Ethics Committee in Biomedical Research—Ministry of Health, 138A Giang Vo, Kim Ma, Ba Dinh, Ha Noi, Vietnam

IEC, Independent Ethics Committee; IRB, Institutional Review Board; N/A, not available.

Table S2 HRQoL: EQ-5D-5L and EORTC QLQ-25 scores for FAS (n=105) and PPS (n=65)

Analysis set	Visit						Mean change from baseline at 18 months (SD)	
	Baseline		12 months		18 months			
	FAS	PPS	FAS	PPS	FAS	PPS	FAS	PPS
EORTC QLQ-PR25								
Urinary symptoms, n	102	64	68	65	80	62	-4.06	-2.39
Mean (SD)	29.38 (19.611)	26.90 (19.688)	21.41 (17.487)	20.48 (14.823)	23.76 (18.619)	24.54 (19.418)	(15.370)	(14.481)
Deterioration, n (%)	-	-	23 (21.9)	23 (35.4)	35 (33.3)	31 (47.7)		
Incontinence, n	55	37	24	24	30	25	1.67 (31.484)	1.67 (31.484)
Mean (SD)	14.55 (26.265)	12.61 (24.026)	5.56 (16.051)	5.56 (16.051)	14.44 (28.612)	16.00 (30.611)		
Deterioration, n (%)	-	-	1 (1.0)	1 (1.5)	4 (3.8)	4 (6.2)		
Bowel symptoms, n	105	65	69	65	80	61	0.31 (9.036)	0.27 (8.046)
Mean (SD)	7.06 (11.011)	5.00 (8.937)	3.02 (5.711)	2.44 (4.824)	6.67 (11.740)	5.60 (10.728)		
Deterioration, n (%)	-	-	7 (6.7)	5 (7.7)	18 (17.1)	13 (20.0)		
Hormone treatment-related symptoms, n	105	65	69	65	81	62	4.68 (11.604)	5.22 (9.903)
Mean (SD)	9.84 (11.690)	6.67 (8.287)	9.15 (9.946)	8.63 (9.370)	13.05 (12.543)	11.67 (10.430)		
Deterioration, n (%)	-	-	18 (17.1)	17 (26.2)	26 (24.8)	21 (32.3)		
Sexual activity, n	105	65	69	65	80	61	-3.54	-2.73
Mean (SD)	13.02 (21.556)	13.08 (22.340)	8.21 (15.023)	7.95 (14.466)	10.00 (20.126)	10.11 (20.923)	(23.224)	(24.567)
Deterioration, n (%)	-	-	8 (7.6)	8 (12.3)	10 (9.5)	8 (12.3)		
Sexual function, n	51	37	30	28	29	23	-8.52	-6.94
Mean (SD)	76.96 (7.447)	78.04 (7.007)	70.42 (17.596)	71.65 (15.819)	69.61 (17.417)	69.84 (17.132)	(15.969)	(15.590)
Deterioration, n (%)	-	-	8 (7.6)	8 (12.3)	6 (5.7)	4 (6.2)		
EQ-5D-5L								
Index score Japan, n	105	65	68	64	81	61	-0.0262	-0.0240
Mean (SD)	0.8162	0.8710	0.8582	0.8585	0.8107	0.8496	(0.17520)	(0.13275)
	(0.18916)	(0.15407)	(0.15046)	(0.15015)	(0.20927)	(0.15240)		
Deterioration, n (%)	-	-	18 (17.1)	17 (26.2)	35 (33.3)	23 (35.4)		
EQ-5D VAS Score, n	105	65	69	65	82	62	2.0 (15.65)	1.8 (11.66)
Mean (SD)	78.8 (13.04)	81.7 (11.95)	83.6 (10.99)	83.7 (10.80)	81.5 (15.76)	83.7 (11.75)		
Deterioration, n (%)	-	-	23 (21.9)	22 (33.8)	32 (30.5)	24 (36.9)		

HRQoL, health-related quality of life; EQ-5D-5L, EuroQol 5-Dimension, 5-Level questionnaire; EORTC QLQ-PR-25, Quality of Life Questionnaire-Prostate Cancer module; FAS, full analysis set; PPS, per-protocol set; SD, standard deviation; VAS, visual analog scale.